Stifel Nicolaus Boosts Inogen (NASDAQ:INGN) Price Target to $7.00

Inogen (NASDAQ:INGN) had its price target boosted by Stifel Nicolaus from $6.00 to $7.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a “hold” rating on the medical technology company’s stock. Stifel Nicolaus’ target price would suggest a potential downside of 14.63% from the stock’s current price.

Other equities analysts have also issued research reports about the stock. William Blair raised shares of Inogen from a “market perform” rating to an “outperform” rating in a research report on Thursday, February 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.00.

Inogen Stock Up 12.3 %

Shares of INGN traded up $0.90 during mid-day trading on Wednesday, reaching $8.20. The company’s stock had a trading volume of 386,291 shares, compared to its average volume of 523,457. The business has a fifty day moving average of $7.07 and a 200 day moving average of $6.50. The company has a market cap of $193.11 million, a price-to-earnings ratio of -1.88 and a beta of 1.10. Inogen has a 1 year low of $4.13 and a 1 year high of $11.98.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, May 7th. The medical technology company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.14. The company had revenue of $78.03 million during the quarter, compared to the consensus estimate of $73.67 million. Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. The business’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period last year, the business earned ($0.63) EPS. On average, analysts predict that Inogen will post -2.56 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in Inogen in the 3rd quarter valued at approximately $52,000. Strs Ohio boosted its stake in Inogen by 282.8% during the third quarter. Strs Ohio now owns 37,900 shares of the medical technology company’s stock worth $197,000 after buying an additional 28,000 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Inogen by 73.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 225,730 shares of the medical technology company’s stock valued at $1,178,000 after buying an additional 95,913 shares during the period. Barclays PLC raised its stake in shares of Inogen by 644.6% in the 3rd quarter. Barclays PLC now owns 49,106 shares of the medical technology company’s stock valued at $257,000 after buying an additional 42,511 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. lifted its holdings in shares of Inogen by 238.7% during the 3rd quarter. Hussman Strategic Advisors Inc. now owns 52,500 shares of the medical technology company’s stock worth $274,000 after acquiring an additional 37,000 shares during the period. Institutional investors and hedge funds own 89.94% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.